At Belay Diagnostics, our mission is to serve patients and those who care for them
An innovative and dynamic approach to evaluating suspected brain tumors
Introducing the most comprehensive liquid biopsy in CSF to help detect and manage primary and secondary central nervous system malignancies
- Genomic profiling plays an essential role in diagnosis, classification, disease monitoring, treatment selection and clinical management for primary and metastatic brain and spinal cord cancers
- Current methods such as cytology and MRIs may lack sensitivity while biopsies are invasive and risky to the patient
- Our breakthrough, high-performance cerebrospinal fluid (CSF) assay is designed to offer a validated and accurate alternative
Your partner in a higher standard of care
Summit™, a novel liquid biopsy test clinically validated in cerebrospinal fluid, offers clinicians an advanced method to help inform diagnosis and treatment decisions for patients with central nervous system malignancies that may preempt biopsy in certain instances.
Introducing the most comprehensive liquid biopsy in CSF to help detect and manage primary and secondary central nervous system malignancies
- Genomic profiling plays an essential role in diagnosis, classification, disease monitoring, treatment selection and clinical management for primary and metastatic brain and spinal cord cancers
- Current methods such as cytology and MRIs may lack sensitivity while biopsies are invasive and risky to the patient
- Our breakthrough, high-performance cerebrospinal fluid (CSF) assay is designed to offer a validated and accurate alternative
Your partner in a higher standard of care
Summit™, a novel liquid biopsy test clinically validated in cerebrospinal fluid, offers clinicians an advanced method to help inform diagnosis and treatment decisions for patients with central nervous system malignancies that may preempt biopsy in certain instances.